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Autosomal recessive polycystic kidney disease (ARPKD; MIM263200) is a severe recessively 
inherited disease of the kidneys and biliary tract, with an incidence of approximately 1 in 
20000 in non-isolated populations. It has a variable clinical spectrum from neonatal demise (in 
30-50%) to survival into adulthood. ARPKD is caused by mutations at a single locus, 
polycystic kidney and hepatic disease 1 (PKHD1), with over 270 pathogenic mutations 
described to date. The high rate of compound heterozygosity in affected individuals has made 
genotype-phenotype correlations difficult. A common missense mutation, p.M627K, in exon 
20 of PKHD1 was identified previously on the majority of ARPKD disease associated alleles 
in the Afrikaans population of South Africa suggesting the presence of a founder effect. 
 
The aim of this study was to describe the clinical phenotype of ARPKD in Afrikaans speaking 
individuals found to be homozygous for the common mutation, and to compare this phenotype 
to previously described cohorts of patients with ARPKD, known to harbour a spectrum of 
mutations. This descriptive study used retrospective data collected from records of patients 
with ARPKD at Johannesburg and Pretoria Academic Hospitals. Twenty seven individuals 
from 24 families were included in the study.  
 
Marked clinical variability was demonstrated within this subject group supporting the 
limitation of genotype-phenotype correlation described worldwide. ARPKD was diagnosed at 
a median age of 27 days, older than a North American cohort (NAC) born after 1990 (median 
age of 1 day). The majority (93%) of subjects in this study were diagnosed with chronic renal 
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insufficiency (CRI) and hypertension (HT), indicating the renal morbidities to be more 
common than noted in previous studies, but occurring at a later median age (1.4 years vs 13.5 
days in the NAC). This may indicate a trend toward milder expression of renal morbidities in 
the present study. Portal hypertension was also diagnosed more frequently (81%) than in 
previous studies but at a younger median age (1.3 years vs 2.8 years), although with similar 
complication rates. Overall statistical correlation was found between the renal and hepatic 
related morbidities in this study, indicating that progression of the condition is not organ 
specific. A survival rate of 89% at one year is comparable to previous studies with similar 
patient ascertainment.  
 
This cohort represents the largest series of patients affected by ARPKD with a common 
mutation, described to date. The findings will provide for more accurate, specific and 
informative genetic counselling in families with ARPKD and may present a resource for 
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Autosomal recessive polycystic kidney disease (ARPKD; MIM263200) is a severe recessively 
inherited disease of the kidney and biliary tract. The principal, invariable features are cystic 
dilatation of the renal collecting ducts, and malformation of the ductal plate with portal tract 
fibrosis. The clinical presentation and progression is variable, although most cases present in 
infancy with an estimated 30% mortality rate in the first year (Zerres et al. 1996). The 
causative gene is polycystic kidney and hepatic disease 1 (PKHD1) (MIM 606702), and there 
is no evidence for locus heterogeneity (Zerres et al. 1994). However, the presence of allelic 
heterogeneity, with more that 270 mutations described to date in the ARPKD-PKHD1 
Mutation Database, Aachen University (2008), has made genotype-phenotype studies 
challenging. 
 
The suggestion of an unusually high frequency of ARPKD in the Afrikaans speaking 
population of South Africa (Lombard et al. 1989), led to the finding in 2002 of a common 
haplotype in the majority of these patients (Professor A Krause, Division of Human Genetics, 
NHLS and University of the Witwatersrand, unpublished data), suggesting the presence of a 
founder mutation. Recent identification of a common mutation (Guay-Woodford et al. 2005) 
in the Afrikaans speaking population confirmed this theory. 
 
The aim of the present study was to describe the clinical phenotype of ARPKD in the 
Afrikaans speaking population, particularly in those patients found to be homozygous for the 
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common mutation, and to compare this phenotype to those found in previous studies of more 
heterogenous groups of patients with ARPKD, known to harbour a spectrum of mutations. 
 
In this introduction, the clinical presentation and diagnosis of ARPKD is discussed. The 
molecular cause and spectrum of mutations is mentioned, with emphasis on the events leading 
to the discovery of a common mutation in the Afrikaans population. The objectives, 
limitations and uniqueness of the present study are outlined. 
1.1 INCIDENCE 
The incidence of ARPKD is estimated to be 1:20 000 world-wide (reviewed in Zerres et al. 
1998b), in non-isolated populations, with a heterozygote frequency of 1:70. However, 
incidence figures vary widely depending on the study population. Kaariainen (1987) found the 
birth prevalence of polycystic kidney disease in the Finnish population to be in the region of 
1:8000 (which may have included some early onset cases of autosomal dominant polycystic 
kidney disease), while Zerres et al (1984) initially estimated an incidence of 1:40 000 in West 
Germany for ARPKD. Although no evidence illustrates an ethnic predominance, ARPKD has 
been reported rarely in non-Caucasian populations (reviewed in Guay-Woodford 1996). In a 
series of South African paediatric patients with renal failure, ARPKD was only found in the 
Caucasian children (Thomson 1997). On the basis of the autosomal recessive mode of 
inheritance the sex distribution is considered equal, but a few reports have suggested a female 
predominance (Gang and Herrin 1986, Kaariainen 1987). 
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1.1.1 Incidence in the Afrikaans Speaking Population 
Lombard et al. (1989) estimated an incidence of 1:11 000 based on the live birth rate, in the 
Afrikaans speaking population of the, then, Transvaal Province of South Africa. This 
translated to a carrier rate of 1:53 in this group, and provided evidence of an unusually high 
frequency of ARPKD in the Afrikaans population.   
1.2 CLINICAL FEATURES OF ARPKD 
1.2.1 Clinical Presentation 
The majority of cases of ARPKD present in infancy (Cole et al. 1987), and they are often 
identified in utero or at birth, hence the previously used term, infantile polycystic kidney 
disease. Blyth and Ockenden (1971) originally proposed the existence of four distinct groups 
of patients (perinatal, neonatal, infantile and juvenile), postulating causation by different 
genetic mutations. It has since become clear that there is significant overlap clinically between 
the groups, and sibships discordant for age, presentation and clinical course have been 
reported (Gang and Herrin 1986, Kaplan et al. 1989a, Deget et al. 1995).  
 
The most common presenting clinical features of ARPKD include enlarged palpable kidneys, 
enlarged liver, respiratory failure, hypertension and urinary tract infections (UTI) (Zerres et al. 
1996). The gross in situ anatomy of an affected infant is shown in Figure 1.1.  
 
Standard diagnostic criteria for ARPKD do not exist but with various modifications, the 
following are usually used (Zerres et al. 1996, Guay-Woodford and Desmond 2003): 
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• Typical ultrasound features of ARPKD (enlarged echogenic kidneys with poor 
corticomedullary differentiation), AND  
• At least one of 
o Patho-anatomic diagnosis of ARPKD in an affected sibling 
o Absence of renal cysts in the renal ultrasounds of both parents (aged >30) 
o Clinical or histopathologic evidence of hepatic fibrosis 
o Parental consanguinity suggesting autosomal recessive inheritance 
 
                                                            
Figure 1.1: Post mortem anatomy of an infant affected with ARPKD* 
 
*The kidneys are massively enlarged but maintain their reniform shape with, in this case, normal fetal 
lobulation. The liver is also enlarged. Photograph courtesy of Prof PD Thomson 
1.2.1.1 Prenatal features and diagnosis  
Affected fetuses may have bilaterally enlarged echogenic kidneys and oligohydramnios on 
fetal ultrasound, but these features are often not seen until late in the second trimester (Zerres 
et al. 1998a) since nephrogenesis is only completed at around 34 weeks gestation. 
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Oligohydramnios, if present, results in development of the Potter sequence: pulmonary 
hypoplasia, characteristic facies and deformities of the limbs (Osathanondh and Potter 1964). 
Massive abdominal distention due to nephromegaly and hepatosplenomegaly has resulted in 
birth dystocia (Blythe and Ockenden 1971). In as many as 70% of cases, however, the precise 
diagnosis can only be made postnatally (Roume and Ville 2004) and thus fetal sonography is 
not considered a reliable method for definitive prenatal diagnosis (Zerres et al. 1998a).  
1.2.1.2 Neonatal presentation  
Severely affected neonates most often present with respiratory difficulties secondary to 
pulmonary hypoplasia resulting from oligohydramnios, attributable to poor renal output in 
utero. Respiratory compromise is exacerbated by abdominal distension due to enlarged 
kidneys, and may result in death (Guay-Woodford 1996). Despite poor renal function, death 
from renal failure is rare at this stage (Blyth and Ockenden 1971, Kaplan et al 1989b). In those 
neonates whose respiratory status does not deteriorate, improvement is noted in their renal 
function (Kaplan et al. 1989a). As many as 30-50% of affected neonates are thought to die 
soon after birth due to respiratory insufficiency (Zerres et al 1998a). 
1.2.1.3 Infancy and childhood features 
For those infants surviving the neonatal period a wide range of renal and hepatic related 
morbidities can evolve, although with marked variability. These include renal failure, 
hypertension, and portal hypertension (Guay-Woodford 1996).  
 
Surviving neonates usually have decreased glomerular filtration rates (GFR) (Guay-Woodford 
1996), but Cole et al. (1987) showed a gradual improvement in renal function over the first 6 
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months in neonatal survivors, and then a decrease after the first year of age. The rate of 
decline is variable and the consequences of renal insufficiency (including growth failure, 
anaemia and osteodystrophy) appear. As treatment for end stage renal failure (ESRF) 
improves, prolonging survival, the hepatic complications may become the predominant 
clinical picture. 
 
Hypertension is the most significant cause of morbidity and mortality among those presenting 
with ARPKD in infancy (Guay-Woodford 1996). It affects the majority of patients either at 
initial presentation or later in the clinical course, and may be severe in young infants requiring 
aggressive treatment to prevent cardiac hypertrophy and failure. Regression of hypertension 
has been documented but the mechanism of this has not been explained (Gagnadoux et al. 
1989). Tubular function abnormalities, with hyponatraemia as a prominent feature in infants 
with ARPKD, are found (Kaplan et al. 1989a), and are thought to result from an inability to 
maximally dilute the urine. Metabolic acidosis is not, however, a significant clinical feature 
(Kaariainen et al. 1988).  
 
A small minority of individuals present as older children or adolescents, providing a 
diagnostic challenge. These patients typically have congenital hepatic fibrosis with relatively 
mild renal medullary ectasia. Their clinical features are mainly a consequence of their portal 
hypertension (Guay-Woodford 1996), and include hepatosplenomegaly, hypersplenism, 
bleeding oesophageal varices and portal thrombosis. ARPKD patients presenting in early 
childhood may also occasionally have dominant liver involvement, while older patients may 
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not have signs of portal hypertension at presentation. Hepatic synthetic function is usually 
normal, as the lesion in ARPKD is confined to the biliary tree. Ascending cholangitis is a 
recognized complication that may result in hepatic failure (Guay-Woodford 1996).  
 
ARPKD is rarely diagnosed in adults (Blyth and Ockenden 1971, Fonck et al. 2001), and the 
clinical course of these patients is not well documented (Adeva et al. 2006). Adeva et al. 
(2006) studied a cohort of 65 patients of whom a third presented in adulthood (>20 years). The 
initial manifestations in these patients were diverse and include renal morbidities 
(hypertension, renal insufficiency) and hepatic morbidities (hypersplenism, upper 
gastrointestinal bleeding and cholangitis). 
 
While recent advances in neonatal care and paediatric renal replacement therapy have altered 
the prognosis for patients with ARPKD, the natural history of the condition still requires 
further characterization (Guay-Woodford and Desmond 2003). 
1.2.1.4 Co-morbidity correlations 
Data from Bergmann et al. (2005) suggest a positive correlation between renal and 
hepatobiliary morbidities, in contrast to the organ-specific progression of disease suggested by 
Guay-Woodford and Desmond (2003) who found no significant correlation between age of 
diagnosis of chronic renal insufficiency (CRI) and portal hypertension. This controversy will 
be explored further in the cohort of homozygous patients included in the present study. 
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1.2.1.5 Survival and renal survival 
Mortality in the first year of life is reported to be between 9 and 24% (Cole et al. 1987, Kaplan 
et al. 1989a, Gagnadoux et al. 1989, Zerres et al. 1996). Kaplan et al (1989a) reported the 
overall survival at one and 15 years to be 79% and 46% respectively. More recently, Guay-
Woodford and Desmond (2003) reported overall patient survival in their cohort of ARPKD 
patients born after 1990, as 85.8% at one month, 78.6% at one year and 74.6% at five years. 
Altogether 58% of the deaths occurred in the first month of life and they were related to 
respiratory insufficiency. Of those who survived the first month, 87% were alive at 5 years. 
Neonatal ventilation requirements were a strong negative predictor of long term survival.  
 
Roy et al. (1997), in their cohort of 52 neonatal survivors with ARPKD, reported actuarial 
renal survival rates of 86% at one year and 67% at 15 years of age, taking the end point as 
glomerular filtration rate < 10ml/min/1.73m2, or the start of dialysis or renal transplant, or 
death due to end stage renal failure. Bergmann et al. (2005) found a comparable renal survival 
rate of 66% at 15 years. 
1.2.1.6 Gender differences 
Zerres et al. (1996) found that girls had significantly more severe disease with respect to 
frequency of urinary tract infections (UTI), growth retardation and renal function, and a higher 
mortality rate than boys with ARPKD. The survival probability at one year was 94% for male 
patients and 82% for female patients. Aside from an increased frequency of UTIs in girls, no 
gender differences were detected in the study by Guay-Woodford and Desmond (2003). 
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1.2.1.7 Sibships 
Kaplan et al. (1989a) reported sibships in six out of eight families as discordant for age and 
mode of onset while Kaariainen (1987) noted consistency among siblings with perinatal 
diagnosis, but more variability among other families. Using the now outdated classification of 
Blyth and Ockenden (1971), dividing ARPKD into perinatal, neonatal, infantile and juvenile 
forms, 11 out of 20 sibships studied by Deget et al. (1995) showed different subtypes among 
affected siblings. In seven families the subtypes were adjacent while only four families 
showed major intrafamilial differences in onset of disease. Eight families however were 
markedly discordant for age at death, suggesting that longevity can often not be predicted 
from the course of an affected sibling. In contrast to the proposals of Blythe and Ockenden 
(1971) however, this study supported the argument for allelic rather than locus heterogeneity. 
More recently, Bergmann et al. (2005) reported marked intrafamilial variability in phenotype 
in 20 of 48 pedigrees with more than one affected child (neonatal death in one and survival 
into childhood in another sibling). 
1.2.2 Pathoanatomical features 
Renal involvement in ARPKD is bilateral and mainly symmetrical, although the gross 
appearance varies with age and extent of involvement. In the neonate the kidneys are large (up 
to 10 times normal weight) but are reniform (Blyth and Ockenden 1971). Cortical extension of 
fusiform collecting ducts is seen on cut section, and the corticomedullary junction is obscured. 
Microscopically, the cysts are of collecting duct origin, with proximal nephron segments being 
structurally normal. The renal pathoanatomical features are shown in Figure 1.2. Dysplastic 
elements are not seen (Guay-Woodford 1996). In patients surviving beyond the neonatal 
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period, increase in renal size and cystic involvement is less extensive, but cysts may expand to 
up to 2cm in size, and are more spherical (Blyth and Ockenden 1971). Interstitial fibrosis 
becomes apparent and kidney size can decrease. 
 
                                                     
Figure 1.2: Renal pathology of autosomal recessive polycystic kidney disease. 
 
A, Kidney of a 2-year-old ARPKD-affected child. Macroscopically, the organ displays multiple small 
cysts on its surface and is severely enlarged, measuring ~15 cm in its longitudinal axis (Gift of Dr. 
Francisco Tibor Dénes). B, Drawing representing the diffuse and radial distribution of dilated 
collecting ducts throughout the cortex and medulla. C, ARPKD renal histology, showing dilation of 
collecting ducts. Image reproduced from Menezes and Onuchic (2006) 
 
 
In ARPKD the liver size may be normal or increased, with a firm texture. Cut section reveals 
fibrous septa often linking the portal tracts. Microscopically, the bile ducts are increased in 
number and there is a varying degree of portal tract fibrosis, small portal vein hypoplasia and 
hepatic arteriolar prominence. Hepatocytes are normal, and gross cysts are unusual, although 
bile ductules are often dilated (reviewed in Guay-Woodford 1996). There are reports of frank 
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cystic dilatation of the entire biliary tree in ARPKD, a condition usually referred to as Caroli’s 
disease (Guay-Woodford 1996). 
1.2.3 Differential Diagnosis 
Autosomal dominant polycystic kidney disease (ADPKD) is the most important differential 
diagnosis, and normal parental renal ultrasounds can virtually exclude this diagnosis (Zerres et 
al. 1998a). Glomerulocystic kidney disease (GCKD) and diffuse cystic dysplasia fall into the 
complex group of diffuse cystic renal diseases along with ARPKD and ADPKD. They often 
present in early life and are variably associated with biliary dysgenesis, but are distinguished 
on sonography, family history and histopathological study (Guay-Woodford et al. 1998). 
Other conditions that require consideration include tuberous sclerosis, juvenile 
nephronophthisis, nephroblastomatosis, bilateral renal vein thrombosis, radiocontrast 
nephropathy and renal involvement in conditions like Meckel-Gruber or Bardet-Biedl 
syndrome (Zerres et al. 1998a). Congenital hepatic fibrosis (CHF) can be associated with 
several of the above as well as Jeune, short rib polydactyly and Ivemark syndromes (Zerres et 
al. 1984), and has been occasionally observed in ADPKD. Congenital hepatic fibrosis may 
also be seen with Caroli’s disease (also seen in ARPKD) and choledochal cysts. 
1.2.4 Prenatal diagnosis 
Definitive prenatal diagnosis by fetal ultrasound is not reliable (Zerres et al. 1998a). 
Ultrasonographic features include increased echogenicity and bilateral symmetrical renal 
enlargement with difficulty in visualization of the fetal bladder. Oligohydramnios may not be 
present, and renal enlargement may not be detected until the second half of pregnancy (Roume 
and Ville 2004). 
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Haplotype-based prenatal analysis for pregnancies at-risk for ARPKD was shown to be 
reliable in all 65 cases assessed by Zerres et al. (1998a), with the proviso of an accurate 
clinico-pathologic diagnosis in a previous sibling, and exclusion of cystic renal disease in both 
parents. Direct mutation analysis of the PKHD1 gene (discussed further below) is a newer 
option for prenatal diagnosis, with the first cases described by Zerres et al. (2004), in families 
where prenatal diagnosis by means of linkage analysis was not possible. 
1.2.5 Management 
Initial management of severely affected infants requires stabilization of respiratory function 
which is compromised by both pulmonary hypoplasia and abdominal distention due to 
nephromegaly. Nephrectomy may be considered, with some potential benefit (MacRae Dell et 
al. 2001). Renal function must be closely monitored, particularly with regard to the urine 
concentrating defects and associated hyponatraemia. These patients are at risk of significant 
dehydration with intercurrent illness (Guay-Woodford 1996).  
 
Hypertension is usually managed with angiotensin-converting enzyme (ACE) inhibitors, but 
may require several medications (Cole et al. 1987). Growth should be optimized with 
aggressive nutrition, and may require nasogastric or gastrostomy tube feeding. Urinary tract 
infections should be treated and other tract abnormalities excluded.  
 
The treatment of chronic renal failure (CRF) in paediatric patients is detailed and discussion 
thereof is too extensive for this text, but in general renal replacement therapy (RRT) in the 
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form of dialysis (peritoneal or haemodialysis) or renal transplant is indicated when children 
become symptomatic or growth failure does not respond to medical management (which may 
include recombinant growth hormone) (Guay-Woodford 1996). Specific to ARPKD, 
pretransplant splenectomy may be indicated if hypersplenism is severe, and nephrectomy may 
be required if the kidneys are massively enlarged. 
 
Close monitoring for the complications of portal hypertension is necessary, with melena or 
haematemesis suggesting the presence of oesophageal varices requiring sclerotherapy or 
variceal banding. Serial ultrasound and Doppler flow studies can be used to monitor the portal 
hypertension. Patients must also be monitored for the development of hypersplenism (Guay-
Woodford 1996). Portocaval shunting and even liver transplantation are therapeutic options. 
Cholangitis can be a difficult problem and must be treated aggressively, with antibiotics. 
 
The psychosocial stresses related to this condition, on both the child and the family, must not 
be underestimated, and should be monitored and managed appropriately. Ultimately 
management requires a multidisciplinary team which includes the paediatrician, paediatric 
nephrologist, hepatologist, specialized nurses, dieticians, genetic counsellor and psychologist 
or social worker. 
1.3 MOLECULAR GENETICS OF ARPKD 
1.3.1 PKHD1 
The ARPKD locus was localized to chromosome region 6p21-cen by genetic linkage analysis 
in 16 families in 1994 (Zerres et al. 1994). This localization was confirmed and refined to a 
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3.8cM interval in families with the severe perinatal form of ARPKD (Guay-Woodford et al. 
1995). Zerres et al. (1998a) found no evidence for locus heterogeneity in this condition. 
Further refinement of the locus and exclusion of a number of candidate genes followed 
(reviewed in Harris and Rossetti 2004). Ward et al. (2002), using a newly described rat model 
(the PCK rat), then identified the human orthologue of Pck, PKHD1 within the ARPKD 
candidate region. Parallel to this, using a positional cloning approach utilizing ARPKD 
patients, Onuchic et al. (2002) independently identified and cloned the PKHD1 gene. These 
studies have provided the basis for direct genotyping in ARPKD. 
 
The PKHD1 gene is an extremely large gene, extending over about 472kb, with the longest 
open reading frame comprising 67 exons and encoding a protein of 4074 amino acids 
(Onuchic et al. 2002 and Ward et al. 2002). Expression studies by these groups suggested that 
PKHD1 and its murine analogue undergo complex alternative splicing patterns, and showed 
high levels of expression of PKHD1 in adult and fetal kidney, and lower levels in pancreas 
and liver.  
 
The predicted protein (fibrocystin/polyductin) represents a putative integral membrane protein 
with an as yet unknown function, localized to the primary cilia and basal body (Wang et al. 
2004).The conserved domains suggest a role as a receptor in collecting duct and biliary 
differentiation (Ward et al. 2002). 
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1.3.2 Spectrum of Mutations 
A number of comprehensive mutation screens have been performed (Bergmann et al. 2003, 
Furu et al. 2003, Rossetti et al. 2003) and to date, more than 270 mutations have been 
described in the PKHD1 gene (ARPKD-PKHD1 Mutation Database, Aachen University 
2008), the majority of which are private. Detection rates of up to 85% have been described in 
the more severely affected groups, with lower rates in the more moderate cases, which may 
indicate inclusion of clinical phenotypes not representing ARPKD (Harris and Rossetti 2004). 
An explanation of locus heterogeneity is not supported by linkage studies (Zerres et al. 
1998b), and the incomplete detection may be explained by intronic mutations and large scale 
rearrangements not detected by the methods used in the above studies (Harris and Rossetti 
2004). 
 
Mutations are spread thoughout the gene with no evidence of clustering at specific sites (Furu 
et al. 2004), and include missense, nonsense, frameshift insertion or deletion and in frame 
deletions as well as mutations altering splicing.  
 
Thus, the size and complexity of the PKHD1 gene in combination with marked allelic 
heterogeneity and compound heterozygosity makes gene-based molecular diagnostics 
complicated, and not routinely available. 
 
 16 
1.3.2.1 Recurrent mutations 
The most commonly reported mutation, c.107C>T (T36M), described in a number of studies, 
accounts for about 15-20% of mutated alleles (Bergmann et al. 2005). It is unclear whether 
this is a mutational hotspot or whether it is due to an ancestral change in the Central European 
population. Evidence seems to indicate that this change is due to a frequent mutational event 
because the C>T change is at a mutagenic CpG dinucleotide, and there are different associated 
haplotypes (Bergmann et al. 2005). Consugar et al. (2005) however found a common 
haplotype in 14 out of 15 alleles with this mutation and estimated an origin for the mutation 
about 49 generations ago. 
 
Two founder mutations (R496X and V3471G) comprise about 60% of PKHD1 mutations in 
the Finnish population (Bergmann et al. 2003), and a specific mutation, 9689delA, is seen in 
the Spanish population (Rossetti et al. 2003), on a single haplotype. Other mutations found in 
multiple studies are I222V, 3761delCCinsG and I2957T, with preliminary haplotype analysis 
indicating the changes to be the result of ancestral mutations (Rossetti et al. 2003).  
1.3.3 Genotype-Phenotype Correlations 
Bergmann et al. (2003) drew preliminary genotype-phenotype correlations for the type of 
mutation present. All patients with two truncating mutations demised early (within the 
neonatal period), indicating that longer term survival requires the presence of at least one 
missense mutation. Other studies by Furu et al. (2003), Rossetti et al. (2003) and Bergmann et 
al. (2004) confirmed this finding. Bergmann et al. (2005), in the first study reporting long-term 
outcome of ARPKD patients with defined PKHD1 mutations, reported a series of 164 neonatal 
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survivors over a mean observation period of six years, and identified no families with 
truncating mutations on both parental alleles. 
 
Missense mutations may range in effect from complete loss of function alleles (similar in 
effect to a truncation mutation), to hypomorphic alleles allowing for a milder clinical course 
(Bergmann et al. 2005), but efforts to assess the genetic contribution of single missense 
mutations to the observed phenotype are hampered by the marked allelic heterogeneity at 
PKHD1. However, attempts are being made to categorise individual mutations into severe and 
moderate or mild changes (Bergmann et al. 2005), comparing the renal phenotypes of 
individuals carrying the same set of PKHD1 mutations. Homozygotes for the same amino acid 
substitutions would be most useful in this regard, but such patients are rare and no large 
groups have been described to date. The group of patients involved in the present study is 
unique in this regard. 
 
The missense mutation R3482C has been seen in two consanguineous Israel-Arab families 
with perinatal demise of five affected children, while affected individuals in a family with the 
T36M mutation in the homozygous state showed intrafamilial phenotypic variability 
(Bergmann et al. 2003). 
 
1.3.4 Modifier Genes 
Recent molecular advances have not answered questions around the factors that modulate gene 
expression. The variability in clinical phenotype, found even within families, is likely to be 
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influenced by modifier genes as well as the environment. Although a human homologue has 
not yet been identified, a modifying gene complex on mouse chromosome 4 is suggested 
(Mrug et al. 2005). Research in this area is active at the University of Birmingham, Alabama, 
USA. 
 
1.4 ARPKD IN THE AFRIKAANS SPEAKING POPULATION 
1.4.1 Incidence and Carrier Rate 
Lombard et al. (1989) investigated 28 families with ARPKD from Pretoria and Johannesburg 
hospitals, and found 92% of these families to be Afrikaans speaking, indicating that ARPKD 
was significantly more common in Afrikaans speakers than in the local English speaking 
community. Based on national statistics for the Transvaal province in 1985, they estimated a 
point prevalence of 1:26 000 for ARPKD. Using the live birth rate, the birth prevalence of 
ARPKD was found to be 1:11 000, the gene frequency 0.0096 and the carrier rate 1:53, in this 
group.  
 
1.4.2 Founder Effect 
The first description of ARPKD in South Africa was by Isdale and Thomson (1973) who 
discussed a series of seven patients at the Transvaal Memorial Hospital for Children, with an 
emphasis on the major clinical features. A decade later they then reported a group of 26 
patients from Afrikaans families with ARPKD (Thomson and Isdale 1984). Lombard et al. 
(1989) postulated that the reason for the relatively high frequency of ARPKD in the Afrikaans 
speaking population in the Transvaal was a result of founder effect. 
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1.4.2.1 A Brief History of the Afrikaners 
South African Afrikaans speaking individuals are descendants of relatively small numbers of 
predominantly Dutch, German and French immigrants who settled in the Cape of Good Hope 
between 1652 and 1701. The settlement arose after the Dutch East India Company established 
a refreshment station there (Nurse et al. 1985). From a group of 1265 individuals in 1701, this 
population grew to 15000 by the turn of the century (Christopher 1976). The majority of this 
expansion was related to large 18th century sibships with high survival potential compared to 
those of Europe at the same time. The rapid growth was thus not immigration dependent and 
the founder population was small (Nurse et al. 1985). It was during this time that the language 
of Afrikaans developed as a dialect of Dutch, spoken in the Cape. 
 
This population growth resulted in a slow development of pressure for more land, and the 
Caucasoid population began to spread. Later German and British immigrants mixed very little 
with the now ‘Afrikaners’. The Great Trek represented a later radiation outward from the 
Eastern frontier of the Cape Colony and involved greater numbers and more rapid movement 
than the earlier movements. The Afrikaners, threatened by the liberalism of the new British 
colonial administration, insecure about conflict and ‘squeezed out’ by their own expanding 
population, hoped to restore their cultural and political unity, and in the decade following 
1835, about 12 000 migrated to the interior, organized into numerous‘trek parties’ under 
individual leaders, many of which remained geographically and socially isolated through the 
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next century. They established the republics of the Transvaal and Orange Free State (South 
African History Online 2008).  
 
1.4.2.2 ‘Founder’ conditions in the Afrikaners 
In the Afrikaners as a founder population, there are a number of dominant and recessive 
conditions found to be relatively common. Classically described is porphyria variegata, a 
dominant disease due to a deficiency of protopophyrin oxidase. Through detailed genealogical 
studies the disease has been traced back to a Dutch couple who arrived at the Cape in 1688 
(Dean 1971). This condition is common in the white and mixed ancestry Afrikaans speaking 
populations and a founder mutation, R59W, has been identified (Meissner et al. 1996).  
 
Other genetic conditions that have been found to be unusually frequent in the Afrikaans 
speaking population include familial hypercholestrolaemia (FH) (Jenkins et al. 1980), lipoid 
proteinosis and sclerosteosis (Botha and Beighton 1983). 
1.4.3 Exclusion of Linkage to 16p 
A study carried out in the Department of Human Genetics, NHLS, Johannesburg, by Ramsay 
et al. (1988) using 14 individuals affected with ARPKD from 12 South African families, 10 of 
whom were of Afrikaans origin, and 10 affected individuals from eight British families, 
excluded linkage of the ARPKD gene to the α-globin gene locus on 16p. The α-globin gene 
locus had been previously linked to a gene for autosomal dominant polycystic kidney disease 




1.4.4 Haplotype Studies 
Work in the Division of Human Genetics, NHLS and University of the Witwatersrand dating 
back to 2002 (Professor A Krause, Division of Human Genetics, NHLS and University of the 
Witwatersrand, personal communication), on DNA collected by Professor P. Thomson (then 
Head of Paediatric Nephrology) from ARPKD patients at Johannesburg Hospital, used 
extragenic linked microsatellite markers to confirm the presence of a common haplotype on 
the majority of disease associated chromosomes. Fifty disease chromosomes were studied, and 
using six markers closely linked to the PKHD1 gene, a full founder haplotype was identified 
on 24 of these chromosomes, with a suggestive founder haplotype on a further nine. Thus, a 
common mutation was proposed to account for the majority of ARPKD alleles in the 
Afrikaans population.  
1.4.5 Founder Mutation 
Sharp et al. (2005) identified a homozygous missense mutation, p.M627K, in two unrelated 
South African patients of Afrikaner origin. Prior to the present study, DNA from a further 25 
unrelated Afrikaner ARPKD patients (most of whom were used in the previous haplotype 
studies) was sent from the Division of Human Genetics, NHLS and University of the 
Witwatersrand, to Dr. Lisa M. Guay-Woodford, Division of Genetic and Translational 
Medicine, University of Alabama, Birmingham, USA for further analysis. Thirteen patients 
(52%) were found to be homozygous for the p.M627K substitution; five (20%) were 
heterozygous for p.M627K and a second PKHD1 mutation (detected by L.Guay-Woodford); 
and one patient (4%) was heterozygous for the p.M627K missense change but no other 
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mutation was identified. Three patients (12%) were found to have other mutations elsewhere 
in PKHD1 (compound heterozygotes), and in the remaining three patients (12%), no mutations 
were detected. Therefore, the p.M627 substitution was detected in 32/50 (64%) of the 
Afrikaner ARPKD alleles tested in that series (Guay-Woodford et al. 2005). 
 
The p.M627K mutation occurs in exon 20 of the PKHD1 gene, at nucleotide 1880. It is a 
missense mutation changing a thymidine to an adenine residue (T>A) and resulting in a 
peptide sequence change from methionine (M) to lysine (K) at position 627. Methionine is a 
polar, uncharged amino acid while lysine is positively charged, and the pathogenic 
consequence, on this basis, is likely to be significant. Conservation of the methionine amino 
acid at position 627 of the PKHD1 protein can be demonstrated across species, further 
supporting the likelihood that a change in this position would alter the protein function. The 
potential functional protein change predicted by the mutation cannot at this stage be assessed, 
since position 357 to 728 of the PKHD1 gene is a poorly characterised region. 
1.5 STUDY OBJECTIVES 
ARPKD is a relatively rare condition, and as such the number of families expected to be 
available for study is small, and then only about 1/3 are expected to be currently in contact 
with nephrology centres in Gauteng. The Nephrology divisions of Johannesburg and Pretoria 
Academic Hospital represent the only specialist centres for the care of children with renal 
disease in the Gauteng province. It is expected therefore, that the majority of children with 
chronic renal disease will have had contact with one of these centres during the course of their 
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illness owing to the need for specialist care, and the paucity of paediatric nephrologists in the 
private sector. 
 
It is the writer’s impression (supported by Lombard et al. 1989) that the majority of children 
assessed for ARPKD in these centres and referred for genetic assessment are of Afrikaans 
origin. Based on this perception, previous haplotype studies, and the recent confirmation of a 
disease causing founder mutation in the majority of Afrikaans patients with ARPKD, the aims 
and objectives of this study can be summarized as follows: 
• To determine the frequency of the founder mutation in those Afrikaans patients shown 
to be clinically affected with ARPKD. 
• To describe the clinical phenotype of Afrikaans patients with ARPKD, particularly 
those shown to be homozygous for the founder mutation.  
• To compare the clinical phenotype of the local genetically homogenous group 
(homozygotes for the founder mutation), with published clinical data from genetically 
heterogenous groups, known to have a spectrum of mutations, in an attempt to 
understand the influence of genotype on the presentation and natural history of 
ARPKD, and indirectly the influence of environment and genetic modifiers on this 
condition. 
• To assess the phenotypic variability of affected sibships within this cohort of 
homozygous patients.  
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1.6 LIMITATIONS OF THE STUDY 
This study recruited patients that were referred to the Paediatric Nephrology Divisions at 
Johannesburg and Pretoria Academic Hospitals. Patients born in other centres and those not 
surviving the neonatal period, may not have been referred, and thus the number of severely 
clinically affected patients is likely to be underrepresented in this study. In addition, the 
private health care sector may be expected to manage a few of the ARPKD patients, but the 
paucity of paediatric nephrologists in this sector, makes this a minor limitation, as few patients 
would have been excluded for this reason. 
 
This study involved collection of predominantly retrospective data from clinical records where 
multiple physicians, including paediatric registrars, may have been involved in patient care, 
and there may thus be inaccuracies in the data relying on clinical examination. Patients born in 
the 1970’s and 1980’s may not have had all the diagnostic evaluations available to patients 
born more recently. Many families of patients who had died or were lost to follow up could 
not be contacted to verify the extent of their Afrikaans ancestry, and thus assumptions were 
made based on the language spoken and the surname as to their ancestry. 
 
In terms of the long term follow up of patients surviving into the third decade, many patients 
were lost to follow-up as they received further care in adult centres and in the private sector, 
where adult services are more widespread than those for paediatric patients. 
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1.7 UNIQUENESS OF THE STUDY 
The majority of previous studies have focused either on the clinical aspects of cohorts of 
patients with ARPKD (Kaplan et al. 1989a, Deget et al. 1995, Zerres et al. 1996, Roy et al. 
1997, Capsidona et al. 2003, Guay-Woodford and Desmond 2003),  without describing 
mutational data, or on describing the molecular aspects and mutational spectrum of this 
condition (Bergmann et al. 2003, Rossetti et al. 2003, Bergmann et al 2004, Losekoot et al. 
2005, Sharp et al. 2005). While attempts have recently been made to combine the clinical and 
molecular data (Furu et al. 2003, Bergmann et al. 2005, Adeva et al. 2006), the level of allelic 
heterogeneity and rate of compound heterozygosity has limited genotype-phenotype 
correlations. The subset of patients in this study is distinct in its homogeneity: the patients are 
homozygous for a common mutation arising on a common haplotype, due to founder effect. 
They thus represent a unique group providing an opportunity to describe the variability in 
presentation and natural history of ARPKD in these patients, and in the future, to study the 
modifiers that may account for the variability. 
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2 SUBJECTS AND METHODS 
2.1 PATIENT ASCERTAINMENT 
This descriptive study used retrospective data collected from records of patients diagnosed 
with ARPKD. Using the diagnostic coding schedules of the Nephrology Units at Johannesburg 
and Pretoria Academic Hospitals, as well as of the Genetic Counselling Unit and Molecular 
Genetics Laboratory of the Division of Human Genetics, NHLS and University of the 
Witwatersrand, a list of potential patients was compiled. 
 
Patients who were in current contact with either the Nephrology Units or the Division of 
Human Genetics were contacted, and consent (and assent where applicable) was obtained for 
further record review as well as for the taking of blood samples from the affected family 
member/s. For patients who had died or had been lost to follow-up, record review was 
conducted and it was ascertained whether blood had previously been collected (during the mid 
1990s) by Professor Peter Thomson, the then head of Paediatric Nephrology at Johannesburg 
Hospital. A number of the patients included in this study were part of the study by Lombard et 
al. (1989). 
 
A conclusive diagnosis, for inclusion into the study, required ultrasound evidence of enlarged 
echogenic kidneys or compatible renal histopathology, and at least one of the following 
criteria: 
 a. Biopsy proven ARPKD in a sibling 
 b. Biliary fibrosis, based on clinical or histopathologic evidence 
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 c. Sonographic evidence of the absence of renal cysts in the parents 
 d. Parental consanguinity 
Of the 76 files reviewed, for which clinical information was available, 10 patients were 
excluded as they did not meet the above criteria. Of those patients (66) who met the criteria, 
58 (88%) were considered to be Afrikaans. 
2.2 DATA COLLECTION 
Data were collected using the Pediatric Polycystic Kidney Disease Registry Primary Data 
Form, developed by Professor L Guay-Woodford (Guay-Woodford and Desmond 2003) (see 
Appendix A), with some modification, particularly with regard to recording the ethnic group 
of the patients. Caucasian patients were sub-classified as Afrikaans with both parents being 
Afrikaans; Afrikaans with one parent Afrikaans and the other parent uncertain/other 
Caucasian; or other Caucasian. Where possible, Afrikaans ancestry was confirmed at the time 
of taking consent. Otherwise, patients who were Afrikaans speaking or had an Afrikaans 
surname, were assumed to have Afrikaans origins. 
 
The data collection form was completed using data from as many of the sources (hospital 
clinical file, genetic counselling file and molecular file) as were available for each individual. 
All the data were collected by the writer and entered manually onto the data collection form at 
the time of collection. For patients still in contact with the Nephrology or Genetics Units, a 
brief interview (based on the Primary Data Form) was conducted when consent was obtained, 
to supplement the data from the files. The parents were also offered further information and 
genetic counselling at the time of taking consent. In addition, the parents were asked to 
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indicate if they would like to be contacted if a specific mutation was identified in their child, 
for the purposes of further genetic counselling and possible carrier testing of other family 
members. Consent was obtained and blood was taken in the clinic setting (at either 
Johannesburg or Pretoria Academic Hospitals) at one of the patient’s regular clinic visits, and 
where possible, blood was taken at the time of other routine blood sampling, to avoid 
additional discomfort. 
 
For the purposes of confidentiality, all patients were assigned a numerical code, and for each 
patient for whom blood was available, or from whom a sample was collected as part of the 
study, this code was linked to a Molecular Genetics Laboratory assigned code which was 
family specific. Only the writer and her supervisors were able to view the originating patient 
name. Professor P Thomson also had access to patient names where clinical data required 
clarification. 
 
Data gathered included the dates of birth, diagnosis, last contact and cause and date of death, 
where applicable. A history of affected siblings, parental consanguinity and prenatal diagnosis 
was obtained, as well as details regarding the neonatal period. Presence and dates of onset of 
renal and hepatic ARPKD related morbidities were recorded, as were results of initial 
radiologic studies and histopathology reports. Information relating to interventions, 
particularly with regard to renal replacement therapies and treatment of the complications of 
portal hypertension, was collected. 
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2.3 MOLECULAR DATA 
Simultaneously with the clinical data collection, existing DNA samples, and those collected 
during the course of the study, from Afrikaans patients with ARPKD, were tested in the 
Molecular Genetics Laboratory of the Division of Human Genetics, NHLS and the University 
of the Witwatersrand for the presence, in the homozygous or heterozygous form, of the 
founder mutation, p.M627K. These data were then linked to the patients for whom clinical 
data had been collected. 
 
Only those Afrikaans patients who met the diagnostic criteria and who were found to be 
homozygous for the founder mutation, were selected for further analysis (27 patients from 24 
families). 
2.4 STATISTICAL ANALYSIS 
Data were transferred into a Microsoft Excel spreadsheet for initial analysis. Means and 
frequencies relating to the data were calculated in Excel. Further analysis of the Afrikaans 
patients who were homozygous for the founder mutation was conducted using the SAS 
(Statistical Analysis Software) statistical package version 9.0 with the assistance of a 
statistician, Mr Eustacius Musenge of the Epidemiology Data Centre of the University of the 
Witwatersrand. 
 
Survival times were calculated using the Lifetest Procedure, from the date of birth to date of 
death or date of last contact, for those who were lost to follow-up. Renal survival times were 
calculated from the date of birth to the date of initiation of dialysis or renal transplant, 
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whichever occurred first. The Means Procedure was used to calculate median and quartile 
ranges for the age of diagnosis of co-morbidities, and associations and correlations between 
co-morbidities were conducted using a two-tailed Fisher’s exact test and Pearson correlation 
coefficients, respectively. For all analyses a p value of <0.05 was deemed significant. 
 
2.5 ETHICS APPROVAL 
Ethics approval for this study was obtained from the Committee for Research on Human 
Subjects (Medical) of the University of the Witwatersrand, certificate number R14/49 Lambie 
dated 26 March 2004 (expiry date 27 February 2009), as well as from the Faculty of Health 
Sciences Research Ethics Committee of the University of Pretoria, certificate number 





The files of 76 patients with a possible diagnosis of ARPKD were reviewed. Ten of these 
patients were excluded as insufficient data were found in the patient’s file to enable the 
researcher to assess whether they met the inclusion criteria, or the diagnosis was incorrect. Of 
the 66 patients who met the inclusion criteria, 58 were thought to be Afrikaans (on the basis of 
their first language and surnames). Molecular data were available for 39 of the 58 Afrikaans 
individuals, from 36 families. Of the 39 individuals, 27 patients from 24 families (one family 
with data from two affected siblings and one family with data from three affected siblings), 
were homozygous for the founder mutation (p.M627K). Ten patients  were compound 
heterozygotes for the p.M627K mutation and another mutation. The second mutation was 
identified in five of these patients (five different mutations), by Professor L Guay-Woodford 
(University of Birmingham, Alabama, USA) as part of a larger sequencing study (unpublished 
data), not discussed here, while the second mutation remains unidentified in the other five. 
Only two of the 39 Afrikaans patients did not carry the p.M627K mutation on either 
chromosome. These findings are summarized in Figure 3.1. Of the 72 alleles tested from 36 
unrelated individuals, 58 (81%) were found to carry the p.M627K mutation. 
 




Of the eight patients who were not Afrikaans, three (from two families) were Indian, three 
(from two families) were of German descent, one was Portuguese and one was of unspecified 
Caucasian descent. There were no Black African patients identified in this series. 
 
66 Patients with confirmed ARPKD
58 Afrikaans










76 ‘ARPKD’ coded files reviewed
 
Figure 3.1: Subject ascertainment and classification 
3.2 PREVALENCE OF ARPKD 
The writer was unable to calculate the birth prevalence of ARPKD in the Afrikaners in the 
Gauteng province because of lack of availability of data on births by population group. The 
point prevalence in Gauteng, the province in which all the patients are or were resident was 
calculated using 2001 censorship data (Statistics South Africa 2008). Of the 746 761 
Caucasians in Gauteng, 452 624 (57%) were Afrikaans. In 2001 there were 29 known patients 
with ARPKD living in Gauteng. The point prevalence was thus calculated to be 1 in 14 678. 
At almost 1 in 15 000 this is a slightly higher estimate than the 1989 point prevalence estimate 
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of 1 in 26 000 for the then Transvaal province (Lombard et al. 1989). Since the point 
prevalence is significantly lower than the incidence, a carrier frequency of 1 in 60, derived 
from the point prevalence, must be an underestimate. Based on the assumption of a 30-50% 
neonatal mortality, the birth prevalence could be between 1 in 7339 and 1 in 10275, and from 
this a rough estimate of the carrier frequency of between 1 in 43 and 1 in 51 is calculated. 
 
3.3 COHORT CHARACTERISTICS 
3.3.1 File review 
The cohort for further analysis comprised 27 Afrikaans subjects (from 24 families) who were 
homozygous for the p.M627K mutation. All the subjects in the subset whose data were 
analysed had molecular files in the Molecular Laboratory of the Division of Human Genetics, 
NHLS, Johannesburg. Various combinations of clinical files from Johannesburg Hospital, 
Pretoria Academic Hospital and the Genetic Counselling Unit at the Division of Human 
Genetics, NHLS were also reviewed (Figure 3.2). Only five (20%) patients had previously 
been seen by the Genetic Counselling Unit. 
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Figure 3.2: Source of clinical files reviewed 
 
3.3.2 Characteristics of the subjects 
The subjects were born between 1969 and 2002, and the record review produced a mean 
observation period (from date of diagnosis to date of death or last contact) of 14.04 years (SD 
8.36 years) and a range of one day to 28.97 years. Figure 3.3 indicates the status of the 
subjects at the time of record review. 
 
Alive             
14 (52%)
Lost to follow 
up                   
7 (26%)
Deaths (3rd 
decade)         
3 (11%) Deaths 
(neonatal)     
3 (11%)
 
Figure 3.3: Patient Status at the time of record review 
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Eleven of the 24 families were in current contact with the nephrology units. For the remaining 
13 families the record review was entirely retrospective, and existing DNA was used for 
mutation testing. 
 
The mean age of the subjects at the time of last contact with the clinic (death or last visit to the 
clinic) was 14.37 years (SD 8.39 years) with a range of one day to 29.69 years. 
 
Altogether, 15 (55.6%) of the patients were male and 12 (44.4%) were female, giving a 
male:female ratio of 1.25. All the patients were Afrikaans speaking and had both parents who 
were of Afrikaans origin. There was no history of consanguinity in any of the families, 
although in one, this information was not specifically available.  
3.3.3 Family History 
There was a family history of more than one child affected with ARPKD in four families. 
Clinical information was available for one sibling pair (who also had a third affected sibling 
on whom there was no information), and a set of three siblings. The other two families had 
two affected siblings, but clinical information was only available for one of the siblings. In 
one of these families there was an early demise, and in the other the Johannesburg Hospital 
file could not be located. 
3.4 CLINICAL FEATURES 
The clinical features of the 27 subjects are detailed in Table 3.1 and summarized in Figure 3.4. 
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Table 3.1 Clinical features of the 27 homozygous Afrikaans subjects with ARPKD 
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Age 
of dx UTI 




































1 M Alive 41 days 
7.7 




days 54 days 54 days No        
2 M Unknown 170 days 
29.4 
















3 M Unknown 1.4 years 
29.7 









4 F Unknown 48 days 
27.3 
years No No No 1 year 
1 





5 F Alive 1 day 
4.6 
years No Yes Yes 1 day 1 day Yes 1 day 1 day 1 day Yes        
6 F Unknown 46 days 
17.7 













7 F Alive 27 days 
13.2 







8 M Unknown 3 days 
17.7 
















9 F Unknown 1.1 years 
16.5 





















10 M Dead 1 day 1 day No Yes No   No    No        
11 M Alive 2 days 
15.3 















12 F Alive 0.9 years 
9.8 
years No No No 1 year 
1 
year Yes 1 year 1 year 1 year No        
13 F Alive 3.4 years 
10.1 








years Yes     8.1 years   
14 M Dead 1 day 1 day No No No   No    No        
15 F Alive 89 days 
11.7 




days 89 days 89 days No        
16 M Alive 29 days 
11.8 










years       
17 M Dead 5 days 
24.1 















18 F Alive 5 days 
15.7 




days 26 days 26 days Yes  
8.0 
years      
19 M Alive 143 days 
13.9 








days No        
20 F Dead 1 day 
24.8 



















21 F Dead 71 days 
21.6 
















22 M Alive 16 days 
14.3 













23 M Alive 44 days 
20.0 









24 M Unknown 1 day 
12.0 
years No Yes Yes 1 day 1 day Yes 1 day 1 day 1 day Yes    
7.2 
years    
25 M Dead 1 day 2 days Yes Yes No 1 day 1 day No 1 day 1 day 1 day No        
26 M Alive 2 days 
12.5 
years Yes No Yes 1 day 1 day Yes 1 day 1 day 1 day Yes        
27 F Alive 2 days 
6.4 








3.4.1 Age of diagnosis 
The age of diagnosis of ARPKD ranged from one day to 3.4 years with a mean of three 
months, but a median of 27 days, since half the subjects were diagnosed in the first month of 
life, and 12/27 (44.4%) in the first week. In only two subjects was the diagnosis suspected 
prenatally on fetal ultrasound. These subjects were siblings, their first sibling having died at 
two days of age of ARPKD. 
3.4.2 Neonatal Characteristics 
Seven subjects (7/27, 26%) required neonatal ventilation, of which two died in the first week 
of life, and one developed chronic lung disease. Hyponatraemia (defined as a serum sodium 
<130mmol/l) developed in nine subjects (9/27, 33%) at a median age of 17 days, with a range 
of one to 137 days. 
3.4.3 Renal related morbidities 
3.4.3.1 Hypertension 
Hypertension was defined as the date of initiation of anti-hypertensive therapy. Hypertension 
was diagnosed in 25/27 subjects (92.6%). The two subjects who were not diagnosed with 
hypertension died on the first day of life, thus all those surviving the first day required anti- 
hypertensive therapy. The age of diagnosis of hypertension ranged from one day to 10.3 years, 
with a median of 122 days. All patients remained on anti-hypertensive therapy until demise or 
loss to follow-up, although the dosages and number of medications required for control were 
not analysed in this study to assess if the severity of the hypertension declined with age. 
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3.4.3.2 Chronic renal insufficiency (CRI) 
CRI was defined as a glomerular filtration rate (GFR) of <75% of normal, adjusted for age, 
based on the estimated method of Schwartz et al. (1976). CRI was diagnosed in 25/27 subjects 
(92.6%). The same two patients, who died within the first 24 hours of life and were not 
diagnosed with hypertension, were not diagnosed with CRI either. The age range of diagnosis 
of CRI was the same as that for hypertension but the median age of diagnosis was 1.6 years. 
 
3.4.3.3 Urinary tract infections (UTIs)  
UTIs were diagnosed in 18/27 subjects (66.7%), with a range of presentation of first infections 
from 27 days to 17.1 years. Fourteen of the initial infections were documented as a cystitis, 
and the remaining four involved the upper urinary tract (pyelonephritis). All the 
pyelonephritides and 10 of the cystitis infections were culture proven. Thus 52% of subjects 
had had a culture proven UTI. 
3.4.4 Hepatic morbidities 
3.4.4.1 Portal hypertension (PHT) 
PHT was diagnosed in 22/27 subjects (81.5%). The diagnosis was based on the presence of a 
persistent palpable splenomegaly of >2cm below the costal margin. The mean age of diagnosis 
was 2.8 years (SD 3.4 years), with the earliest at 40 days, and the latest at 11.2 years. Of the 
five subjects in whom splenomegaly was not detected, three died in the neonatal period, one 
was 17.7 years at loss to follow up and one was 13.9 years at last contact.  
3.4.4.2 Variceal bleeding  
Variceal bleeding was only documented in three subjects, at 5, 8.1 and 10 years respectively. 
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3.4.4.3 Hypersplenism  
Hypersplenism, defined as a platelet count persistently <140x109/l, was found in 14/27 
subjects (51.9%) at a mean age of 6.7 years (SD 4.3 years, with a range of 1.8 - 15.9 years).  
3.4.4.4 Cholangitis  
Cholangitis was only diagnosed in one subject. 
3.4.5 Growth 
Sixteen subjects (16/27, 59.3%) showed growth retardation (defined as a height for age <3rd 
centile on the CDC 2000 charts) (National Center for Health Statistics 2008). All of these 
patients had hypertension and CRI, and 10 (63%) required renal replacement therapy (RRT) 
(dialysis or renal transplant). Excluding the three patients who died in the neonatal period, of 
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Figure 3.4: Summary of the clinical features of patients with ARPKD 
 
3.4.6 Gender differences 
As illustrated in Table 3.2, no significant differences were detected between males and 
females in terms of the various morbidities, except for UTIs which were found to be 





Table 3.2: Morbidity in males and females with ARPKD 
 
MORBIDITY MALES (n=15) FEMALES (n=12)  P-VALUE* 
Hyponatraemia 4 5 0.4479 
Growth retardation 10 6 0.4517 
Hypertension 13 12 0.4872 
CRI 13 12 0.4872 
UTI 
 
7 11 0.0192 
Portal hypertension 11 11 0.3419 
Hypersplenism 8 6 1.0000 
 
* Fisher’s exact test for small samples (two-tailed) 
 
3.5 CORRELATION AMONG ARPKD COMORBIDITIES 
The writer investigated the correlations between renal (CRI and hypertension) and hepatic 
(splenomegaly) morbidities by age of diagnosis. Persistent splenomegaly was used as an 
indicator of raised portal venous pressure. Statistically highly significant correlations were 
noted overall and in the male subgroup between CRI and hypertension, between CRI and 
splenomegaly, and between hypertension and splenomegaly . Despite this, none of these 









Table 3.3: Correlation between renal (CRI and hypertension) and hepatic 




CRI   0.68 (p=0.0002) 
   Male (13) 
  
0.85 (p=0.0002) 
   Female (12) 
  
0.15 (p=0.65) 
Splenomegaly 0.71 (p=0.0003) 0.79 (p<0.0001) 
   Male (11) 0.93 (p<0.0001) 0.94(p<0001) 
   Female (11) 0.097 (p=0.78) 0.16 (p=0.64) 
 
3.6 IMAGING FINDINGS 
All except one subject, who died at 24 hours of age and whose diagnosis was made 
histopathologically, had renal imaging performed. This was done at a median age of 75 days 
(range one day to 11.5 years). Twenty-two of the 26 subjects had renal sonography performed, 
of which nine were reported to have echogenic kidneys without gross cysts, two had 
echogenic kidneys with gross cysts visible, and one had an incomplete record, reported as “in 
keeping with ARPKD”. Of those patients who had initial imaging, but not sonography, three 
had intravenous pyelograms (IVPs) and one had computerized tomography (CT) of the 
abdomen, and all were reported as consistent with ARPKD. 
 
Liver imaging was performed in 18 subjects and at a median age of 1.1 years (range 1 day to 
9.4 years). Sixteen subjects had sonography performed, of which nine cases were reported as 
normal, six as “echogenic” and one reported visible ‘cysts’. Two subjects had CT scans in 
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which the radiologist commented on dilated bile ducts in one and on the presence of ‘cysts’ in 
the liver in the other. 
3.7 PATHOLOGIC FINDINGS 
Only six of the 27 subjects had renal histopathological studies: two were performed at the time 
of autopsy, two at the time of nephrectomy, and two at biopsy (one open and one needle 
biopsy). All six had evidence of dilated collecting ducts and an absence of dysplastic elements 
and glomerular dilatation. Eight subjects had liver histopathological studies performed, six at 
biopsy (five of which were open), and two at autopsy. All were reported as either having 
biliary dysgenesis or fibrosis. 
3.8 MANAGEMENT 
3.8.1 Renal replacement therapy 
Thirteen subjects (13/27, 48%) required renal replacement therapy, 12 of who had renal 
transplants (with or without dialysis) and one who remained on renal dialysis without a 
transplant at the time of last contact. 
 
Six subjects (6/27, 22%)  required renal dialysis and of these four had peritoneal dialysis only, 
one had haemodialysis only and one required both (at different times). Dialysis commenced at 
a mean age of 13.6 years (SD 3.1 years). Of the six subjects requiring dialysis, in three this 
was preceded by preemptive failed renal transplants, another two subsequently had successful 
renal transplants and one continues on dialysis at this time. Overall 12 subjects have had renal 
transplants, at a mean age of 13.7 years (SD 3.7 years, range 6.2 to 18.7 years at first graft). 
Five of the 12 were from living related donors and the remainder were cadaver transplants. Six 
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grafts were lost due to chronic rejection and the other six were functioning at the time of this 
study. Four subjects have had a second transplant, at a mean age of 18.3 years (SD 2.6 years), 
two of which were acutely and two were chronically rejected.  
3.8.2 Interventions for hepatic related morbidities 
Ten subjects (10/27, 37%) required a form of intervention for a hepatic related morbidity. One 
subject was recorded to have had variceal banding performed (at 8.1 years), five to have had 
splenic shunts, at a mean age of 10.9 years, and three to have had embolisation of the splenic 
artery, at a mean age of 9.2 years. Three patients had splenectomies, at a mean age of 12.3 
years (including the one who had the banding and another who also had a shunt procedure). 
3.9 SURVIVAL 
3.9.1 Patient survival 
Of the whole Afrikaans subject group (58 patients), 11 (19%) died at less than one month of 
age, while in the group homozygous for the p.M627K mutation (27 patients), three (11%) died 










Table 3.4: Survival rates based on age at last contact in the homozygous group 
 
 Age Male (n=15) Female (n=12) Overall 
1yr 12/15 (80%) 12/12 (100%) 24/27 (89%) 
5yrs 12/15 (80%) 12/12 (100%) 24/27 (89%) 
10yrs 12/15 (80%) 12/12 (100%) 24/27 (89%) 
15yrs 12/15 (80%) 12/12 (100%) 24/27 (89%) 
20yrs 12/15 (80%) 12/12 (100%) 24/27 (89%) 
25yrs 9/15 (57%)  4/12 (33%) 13/27 (48%) 
 
The overall mean survival was 21.45 years (SE 1.67 years), with a mean survival in males of 
19.33 years (SE 2.88 years) and in females of 23.70 years (SE 1.24 years). The difference 
between male and female survival was not statistically significant. The Kaplan Meier survival 




Figure 3.5: Kaplan Meier survival graphs for males and females 
 *○ (males)/○ (females) Last age of contact for subject still alive/ lost to follow up 
 
3.9.2 Cause of death 
Of the three neonatal deaths, all were male and all were due to respiratory failure. Two of 
these subjects were unsuccessfully ventilated and the other could not be resuscitated for 
mechanical ventilation. The three other documented deaths occurred at 24.2, 24.8 and 21.6 
years of age, two due to renal failure (one of whom had had two, and the other, one renal 
transplant), and the third due to hepatic failure. 
3.9.3 Renal survival 
Renal survival was calculated from birth with an end point at the start of renal replacement 
therapy (dialysis or renal transplant). These data are presented in Table 3.5. 
Age (years) 
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Table 3.5: Renal survival rates in the homozygous group 
 
  Male (n=15) Female (n=12) Overall 
5yrs 15/15 (100%) 12/12 (100%) 27/27 (100%) 
10yrs 15/15 (100%) 10/12 (80%) 25/27 (91%) 
15yrs 10/15 (67%) 6/12 (53%) 18/27 (61%) 
 
The overall mean renal survival was 14.72 years (SE 0.75 years), with a mean survival in 
males of 15.61 years (SE 0.66 years) and in females of 13.54 years (SE 1.43 years). The 
difference between male and female survival was again not statistically significant. The renal 




Figure 3.6: Kaplan Meier renal survival graphs for males and females 
 *○ (males)/○ (females) Last age of contact for subject still alive/ lost to follow up 
 
3.10 SIBSHIPS 
Of the four families in which more than one affected sibling was reported, only two families 
had sufficient data on more than one sibling for inclusion into the study. Detailed comparisons 
of the clinical features within sibships could thus not be made. However the ages of death or 






Table 3.3: Survival differences in families with more than one affected sibling 
 
  Sib 1 Sib 2 Sib 3 
Family 1 Died at 5m* Alive at 29y* Alive at 29y* 
Family 2 Died <1m Alive at 12y* Alive at 6y* 
Family 3 Died <1m Alive at 13y*   
Family 4 Alive at 15y* Alive at 15y   
 * Subjects included in the clinical analysis in this study 
 
3.11 COMPARISON WITH PUBLISHED DATA 
A comparison of some of the clinical characteristics was made with the largest group of 
patients described to date, that of the North American cohort (NAC) (Guay-Woodford and 
Desmond 2003). The patients in this cohort were subdivided into those born before 1990 and 
those born in or after 1990 (43 and 166 patients respectively). The latter group was used for 
the comparison in Table 3.7. Data from the NAC patients born before 1990 was not available 
for this comparison. The genotypes of the NAC patients were not described but they would 
have represented a wide variety of mutations, the majority being compound heterozygotes.  
 
The Afrikaner cohort demonstrates a later median age of diagnosis of ARPKD (27 days vs. 
one day), as well as of hypertension (104 vs. 16 days) and CRI (515 vs. 16 days). Renal 
transplant was also performed at a later median age in the present cohort (14.6 vs. 4.4 years). 
In contrast, hepatic morbidity: PHT (splenomegaly) was diagnosed at an earlier median age in 
the Afrikaner cohort although a complication thereof (variceal bleeding) presented later (8.1 




Table 3.4: Comparison of clinical characteristics by age of onset of morbidity 
 
Characteristic Afrikaner cohort (N=27) 
(Present study)  
 
Median (25th%-75th%) 
North American cohort 
(N=166) 
(Patients born after 1990) 
Median (25th%-75th%) 
Diagnosis 27d (2-89) 1d (1-61) 
Hyponatraemia 17d (3-65) 16d (1-46) 
Hypertension 104d (5-378) 16d (5-165) 
CRI 515d (79-1443) 13.5d (1-394) 
Splenomegaly 1.3y (0.3-3.4) - 
Portal hypertension - 2.8y (0.9-4.7) 
Variceal bleeding 8.1y (5.0-10.0) 5.9y (4.0-6.0) 
Renal transplant 14.6y (11.5-15.8) 4.4y (1.5-6.9) 
Liver transplant - 8.2y (5.4-10.0) 
Death 10.8y (incl 3 NN deaths) 10d (1-93) 
 
 
A more detailed comparison of our findings with nine previous studies, including the NAC, 
and completed between 1989 and 2005, can be found in Appendix B, based on the table 
presented in Bergmann et al. (2005). The lack of prenatal diagnosis in the present study is 
evident, compared to between 11% (Zerres et al. 1996) and 46% (Guay-Woodford and 
Desmond 2003) of diagnoses made prenatally in other studies. Growth retardation was 
diagnosed relatively more often in the present study (59%), compared to between 6% 
(Kaariainen et al. 1988) and 25% (Zerres at al. 1996) in other studies. Altogether 93% of 
subjects in the present study had CRI, but this is not directly comparable to criteria used to 
define renal failure or insufficiency in other studies. The survival rates at five years appear to 
be minimally higher in this study (89%) compared to other studies which report between 75% 
(Guay-Woodford and Desmond 2003) and 84% (Bergmann et al. 2005). While the mortality in 
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the first year in this study was 11%, other studies reported between 9% (Zerres et al. 1996 and 




4.1 ALLELE FREQUENCY 
Collaborative studies between the Division of Human Genetics (NHLS and University of the 
Witwatersrand) and Professor L. Guay-Woodford (University of Birmingham, Alabama, 
USA) on 25 unrelated patients with a presumed diagnosis of ARPKD found the p.M627K 
mutation on 64 % of alleles tested (Guay-Woodford et al. 2005). In the present study, of 39 
families (36 unrelated individuals) meeting the inclusion diagnostic criteria for ARPKD (some 
of whom may have been included in the earlier studies), the p.M627K mutation was found on 
81% of alleles tested. The latter figure is likely to be more accurate since some of the patients 
tested initially were, on clinical review, found to have ADPKD or another diagnosis. While 
the present study utilized DNA from a number of the patients tested in 2005, the strict 
application of the inclusion criteria allowed for a diagnostically more specific group. 
 
This finding represents the highest frequency of a single mutation in a specific population 
group documented worldwide, to date. The two mutations found recurrently in Finnish 
patients with ARPKD together account for 60% of disease associated alleles (Bergmann et al. 
2003), and reports of the recurrent mutation documented in the Spanish population recorded 
only two individuals who were homozygous for that mutation (Rossetti et al. 2003).  
 
The finding of the p.M627K mutation in 81% of ARPKD disease associated alleles in the 
Afrikaner population has important diagnostic implications: an Afrikaans patient presenting 
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with a suspected clinical diagnosis of ARPKD can be tested for this mutation. p.M627K, in the 
homozygous form, will confirm the diagnosis of ARPKD, and if found in the heterozygous 
form will be highly supportive of the diagnosis in conjunction with the clinical findings. 
Should the p.M627K mutation not be detected (as would be expected to occur in 3.6% of 
affected Afrikaans patients, in a population assumed to be in Hardy-Weinberg equilibrium), 
further investigation (invasive testing or sequence analysis of the PKHD1 gene) may be 
indicated to confirm the diagnosis. The cost-effectiveness and relative ease of such a DNA 
based diagnostic test for this population is self evident.  
 
The serious implications for those affected with ARPKD makes requests for prenatal 
diagnosis, for couples who have had a previously affected child, not uncommon. Linkage 
analysis, as mentioned in the introduction, has a number of limitations, including the need for 
DNA from a previously affected sibling and a confirmed histopathological diagnosis in that 
sibling. For affected siblings found to be homozygous for the p.M627K mutation, or in the 
absence of DNA from the sibling, where both parents are found to be carriers of this mutation, 
prenatal diagnosis can be offered more quickly, less expensively and more accurately than 
linkage analysis in the Afrikaans population. 
4.2 PREVALENCE 
4.2.1 ARPKD in the Gauteng Province 
The estimated point prevalence in this study, of 1 in 14 678 based on 2001 censorship data 
(Statistics South Africa 2008) is higher than the 1 in 26 000 reported by Lombard et al. in 
1989, for the then Western Transvaal. This difference may have a number of explanations. 
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The more recent point prevalence may reflect improved survival of patients with more 
advanced neonatal care and improved management of renal morbidities. Although the figure 
may partly reflect better patient ascertainment, this is unlikely as the original studies were 
conducted by the nephrologists who were themselves managing the majority of paediatric 
renal problems in the province. Alternatively, the changing provincial borders in the mid 
1990’s means that the population base for the estimations have changed making comparison 
more difficult. However, the majority of affected families tend to be concentrated close to the 
tertiary care centres in Johannesburg and Pretoria (in Gauteng), and these centres were also 
included in the then Western Transvaal.. 
 
The 2001 censorship data did not provide information on birth by population group. From the 
data presented in this study (point prevalence), a birth prevalence of between 1 in 7339 and 1 
in 10275 based on a 30-50% neonatal mortality (Zerres et al. 1998b) can only be estimated. 
Again, these figures are slightly higher than the 1 in 11 000 estimated by Lombard et al. 
(1989).  
 
Lombard et al. (1989) calculated a carrier frequency, based on the birth prevalence of ARPKD 
in the Afrikaans population of 1 in 53, only slightly lower than the estimation of between 1 in 
43 and 1 in 51 arising from the present study. Assuming 81% of the ARPKD associated alleles 
in this population carry the p.M627K mutation, the carrier rate for this specific mutation 
would be expected to be in the region of 1 in 54 to 1 in 64 Afrikaans individuals in the 
Gauteng province. The Human Genetics Molecular Laboratory at the NHLS has subsequently 
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screened 98 random Afrikaans individuals for this mutation and found one p.M627K mutation 
(Professor A. Krause, Division of Human Genetics, NHLS and University of the 
Witwatersrand, personal communication). This small sample of screened individuals is of 
course insufficient to accurately determine a carrier rate, but 1/98 is not out of keeping with 
the above estimations. 
4.2.2 ARPKD in the Rest of South Africa 
Communication between the writer and consultants in Paediatric Nephrology in other referral 
centres in South Africa has raised some interesting observations. Dr P.Gajar at Red Cross 
Children’s Hospital and Dr P.Nourse at Tygerberg Hospital, both in the Western Cape, report 
that they together currently manage six Afrikaans speaking patients of Caucasian origin, from 
five families, with ARPKD. One of these patients recently arrived from Gauteng and had been 
included in the present study. In addition, they manage two Afrikaans speaking patients of 
mixed ancestry, and two Caucasian patients with no Afrikaner ancestry. Prof  J. Cronje, at 
Universitas Hospital in Bloemfontein reports that they manage no patients with ARPKD, 
while the same applies at King Edward Hospital in Durban. This is in contrast to the 18 
patients currently managed at Johannesburg and Pretoria Academic Hospitals (most updated 
figures, April 2007). Again, using 2001 census data (Statistics South Africa website 2008), 
since more updated population statistics are not available, this indicates that ARPKD is 
presently 1.4 times more common in the white Afrikaners in Gauteng (population 1003860), 
compared to white Afrikaners in the Western Cape (population 461522). 
4.2.2.1 ARPKD in Black South Africans 
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Of the 66 patients ascertained to have ARPKD only eight, from six families, were not of 
Afrikaans origin, and none were considered of to be of Black South African descent. This is in 
keeping with the findings of Thomson (1997). Communication between the writer and doctors 
at Chris Hani Baragwanath Hospital, where staff of that Nephrology Unit attend to the 
paediatric population of Soweto and serve mainly Black patients, revealed no additional 
confirmed cases of ARPKD. Again, early neonatal demises attributable to ARPKD may have 
not been diagnosed, but there remain no confirmed cases of ARPKD in Black South Africans. 
4.2.3 Possible Causes for the Difference in Prevalence in Different Regions of 
South Africa 
Lombard et al. (1989) also observed that there was an apparent concentration of ARPKD cases 
in the western Transvaal. A similar geographical clustering was observed by Torrington et al. 
(1984) with respect to FH. Torrington et al. (1984) associated FH with the religious affiliation 
of their patients to the Gereformeerde Kerk established in 1859. They discussed the formation, 
following the migration of Afrikaans speaking trekkers from the Cape in the mid 1800’s, of a 
genetic isolate based on sociological and geographical factors, supporting the theory of 
founder effect in FH. 
 
The finding of a founder mutation in the white Afrikaans patients with ARPKD in Gauteng, 
and the apparent concentration of patients in this region of the country may also be attributed 
to the initial rapid expansion of the population in the Cape and the subsequent discrete trek 
party migrations to the interior, with relative social isolation over the following decades. The 
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results of inbreeding in a small subgroup of Afrikaners, may have lead to expression of this 
recessive condition at increased frequency in a relatively localized area of the country.  
 
The p.M627K mutation has not been described in any of the European populations from which 
the Afrikaners may have originated (ARPKD-PKHD1 Mutation Database, Aachen University 
2008). More detailed and extensive haplotype studies might have the potential to date the 
origin of this mutation more accurately. 
4.3 PATIENT ASCERTAINMENT 
Determination of whether an individual is ‘Afrikaans’ is not always simple. Simply speaking 
the Afrikaans language or having an Afrikaans surname does not exclude more recent 
admixed ancestry and conversely, a surname that is not Afrikaans does not exclude a close 
Afrikaans ancestry. As an example, one pair of ‘Afrikaans’ siblings, who were found in a 
previous study (Onuchic et al. 2002) to be compound heterozygotes for an I2944fsX2949 
mutation in exon 58 and an I222V mutation in exon 9, were, on direct questioning of the 
mother, found to be of recent German descent on both the maternal and paternal sides of the 
family, excluding them as descendents of the Afrikaans founder population. For the purposes 
of this study, where possible, Afrikaans ancestry was discussed with the parents. In the 
absence of such a history, documentation of languages spoken by the parents and surnames of 
the parents were used to classify the individuals. In the 24 families with homozygous 
p.M627K affected offspring, there was clear predominance of Afrikaans ancestry. 
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The likelihood of under representation of subjects who died in the postnatal period of ARPKD 
related complications, either undiagnosed or not referred for tertiary care, has been mentioned 
and is a significant limitation in fully describing this subject group of homozygous patients. 
However the paucity of facilities and specialists for treatment of the longer term renal 
complications of this condition means that the majority of survivors of the neonatal period are 
likely to have been ascertained by this study. 
 
The availability of DNA for molecular analysis in only 39 of the 58 confirmed cases of 
ARPKD in Afrikaners is limiting, but could not be overcome as the majority of these patients 
had died years to decades previously. 
 
Only the 27 subjects homozygous for the p.M627K mutation were chosen for the clinical 
component of the study, as one of the study objectives was to establish if the molecular 
homogeneity of the group in anyway made them distinguishable from the molecularly 
heterogeneous groups described previously. The patients who carry a single p.M627K 
mutation are compound heterozygotes for a number of different mutations, five of which were 
previously identified, and would have diluted the homogeneity of the former group. Of the 
five other mutations identified, all were different. The 10 compound heterozygotes remain an 
important resource for future modifier gene and genotype-phenotype correlation studies. 
4.4 COHORT CHARACTERISTICS  
The subject group of this study included patients born up to 39 years ago (in 1969) and thus 
caution is required in describing the clinical course of such patients, particularly when 
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comparing them with those born more recently, given the advances in neonatal intensive care, 
anti-hypertensive therapy and renal replacement therapy. However, the long mean observation 
period of 14 years in the present study is significant, as one of the largest long-term clinical 
studies (Bergmann et al. 2005) of 164 patients, reported a mean observation period of only six 
years. 
 
About half the patients were alive at the time of the present study, and of these, 11 families 
were in contact with the nephrology units involved, allowing for the collection of more 
accurate clinical information, as well as for feedback to the families with the offer of carrier-
testing in those at risk who request it. Just less than a quarter (six) of the patients had demised, 
and slightly more (seven) were lost to follow up, mainly as they transferred out of the confines 
of the paediatric setting into the more widespread adult nephrology services. Attempts were 
made, as far as possible, to trace these patients, but with little success. 
 
The male:female ratio of patients of 1.25 is compatible with the autosomal recessive mode of 
inheritance in a group of this size.  
4.5 CLINICAL FEATURES AND COMPARISON WITH PUBLISHED 
DATA 
In discussing the clinical features of this subject group (homozygous for the p.M627K 
mutation) (N=27), the data will be compared with those of other clinical cohorts (see appendix 
B), particularly of the North American Cohort (NAC) (Guay-Woodford and Desmond 2003), 
the largest clinical cohort described to date. This cohort was divided into a younger group 
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(n=166) born in or after 1990 and an older group born before 1990 (n=43). The characteristics 
of the NAC of 166 patients born after 1990 are summarized in Table 3.7 in the results section 
of this report. 
4.5.1 Age at diagnosis 
A median age of diagnosis, in our cohort, of 27 days (and mean age of 120 days), compared to 
the median age of one day in the subset of the NAC, born after 1990 (46% of whom were 
diagnosed prenatally), may indicate a bias in the present study toward inclusion of subjects 
that survived the neonatal period. The older NAC (n=43), born before 1990, had a median age 
of diagnosis of 72 days, even later than that of the present study, possibly reflecting the same 
bias. Availability of prenatal ultrasound in the developed world, particularly subsequent to 
1990 (when the younger NAC patients were born), as well as earlier referral to tertiary centers, 
could account for the earlier median age of diagnosis in that group. The quartile ranges of age 
at diagnosis are not dissimilar among the subjects in the present study and the younger NAC. 
4.5.2 Renal related morbidities 
Hyponatraemia was diagnosed in nine (33.3%) of the subjects in this study, compared to 
26.5% in the younger NAC, with a very similar median age of diagnosis (17 vs 16 days of 
life). Kaariainen et al. (1988) who studied a cohort of 18 patients also diagnosed 
hyponatraemia in 33%, but Zerres et al. (1996) found hyponatraemia in only 7/115 (6%) of his 
West German patients. The explanation for this difference is unclear, but a larger proportion 
(25%) of Zerres’ subjects was diagnosed with ARPKD at >1 year of age compared to 12% and 
16% in ours and the younger NAC respectively, thus his figures may represent an 
underestimate of the frequency of hyponatraemia in this condition. 
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Almost all (93%) of our cohort, but only 65% of the younger NAC, developed hypertension. 
The NAC showed an early median age of diagnosis (16 days) compared to the present study’s 
104 days. The mean age of diagnosis of hypertension in the local group was 490 days (1.3 
years). Again, a number of factors, including later referral and a wide range of age at diagnosis 
(latest at 10.3 years in the present study) make direct comparison problematic.  
 
Similarly, CRI was found in 93% of our subjects, but in 42% of the NAC (similar in the older 
and younger cohorts). Bergmann et al. (2005) found CRI in 86% of their cohort of 164 
subjects. In contrast to the median age of diagnosis of CRI in the younger NAC patients of 
13.5 days, the older NAC patients were diagnosed with CRI at a median age of 3.7 years. The 
criterion for diagnosis of CRI remained unchanged thus this difference may reflect the later 
age of diagnosis of ARPKD in the older cohort. The subjects in the present study were 
diagnosed with CRI at a median age of 515 days (1.4 years), but a mean of 962 days (2.6 
years), the increased mean reflecting the wide range of age at diagnosis (1 day to 10.3 years).  
 
It is worth noting that the patient diagnosed with hypertension and CRI at 10.3 years was 
diagnosed with ARPKD at 0.46 years (6 months) of age and had constant follow-up – thus, the 
later mean age of diagnosis of HT and CRI in the present study is not entirely a result of late 
referral, but is also skewed by one individual who developed hypertension later in the course 
of the disease. The younger median age of diagnosis of CRI in the younger NAC (13.5 days), 
compared to 1.4 years in this study, may partly reflect earlier referrals and ascertainment, but 
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may also indicate a milder phenotypic expression of the renal morbidity in homozygotes for 
the p.M627K mutation. Further exploration of this suggestion is severely limited by the lack of 
consistent criteria among studies used to document the progression of renal disease. 
 
Culture proven UTIs in 52% of our patients compared to the 18.5% in the younger NAC is 
likely to reflect the longer observation period in our patients. 
4.5.3 Hepatic related morbidities 
Splenomegaly was used as a clinical marker for portal hypertension (PHT) in the present study 
since a persistently enlarged spleen in the context of ARPKD is likely to indicate raised portal 
venous pressure. Hepatomegaly was considered a poor marker for portal hypertension, as it is 
not reflective of venous pressures in the portal system, but rather of the concomitant primary 
hepatic pathology. A clinical marker was chosen because the vast majority of subjects, 
particularly the older subjects, did not undergo detailed imaging or Doppler studies of the 
portal vein, and if they did, this was not performed serially. This is important as other studies, 
for example that of the Guay-Woodford and Desmond (2003), used sonographic evidence of 
hepatomegaly, splenomegaly and directional reversal of portal vein flow as their definition of 
PHT, and the results may therefore not be directly comparable.  
 
The median age of onset of splenomegaly was 1.3 years in the 81% of subjects in our cohort 
who developed PHT, with a range of 40 days to 11.1 years, and an average age of 2.7 years. 
The median age is younger than that of the younger NAC (2.8 years), in whom only 15% and 
34% of the younger and older cohorts respectively, had evidence of portal hypertension. The 
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study of Bergmann et al. (2005) showed evidence of portal hypertension in 44% of their 
patients and splenomegaly in 38%. No other study has recorded as high an incidence of PHT 
as the present study (see Appendix B). While this may indicate that patients with the 
homozygous p.M627K mutation are more likely to develop PHT, the progress and 
implications thereof are more difficult to assess, due to the limitations of the clinical marker in 
the present study, retrospective data and minimal investigation that could be performed locally 
over the last 30 years. In addition, our long observation period and bias toward long term 
survivors may be the reason splenomegaly was ultimately documented in such a high 
proportion of our subjects.  
 
A complication of PHT, variceal bleeding, occurred in 10.8% of the older NAC patients and, 
comparably, 11% of the patients in the present study. The similar complication rate is 
unexpected, since the incidence of PHT (splenomegaly) is higher in the local series. This 
could indicate that the PHT in the local series has a milder, less complicated clinical course, or 
that the incidence of PHT in the present study has been overestimated, for reasons mentioned 
above.  
4.5.4 Growth 
Growth retardation (GR), defined as height for age <3rd percentile on the CDC 2000 growth 
charts (National Centre for Health Statistics 2008), was documented in 16/27 (59%) subjects 
in this study. Direct comparison with other studies in Appendix B is difficult because of the 
differing criteria used to define GR. Bergmann et al. (2005) showed GR in 16% of subjects, 
similar to the 18% found by Gagnadoux et al. (1999), but these studies used definitions of 
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<2SD and <4SD below the mean height for age, respectively. Guay-Woodford and Desmond 
(2003) found GR in 24% of their subjects (also using <2SD below mean height for age as their 
definition of GR). Zerres et al. (1996) found GR in 25% (height <3rd percentile for age) with 
evidence of reduced GFR in the majority (24/28) of patients with GR. Konrad et al. (1995) 
ascribed growth retardation in patients with ARPKD to the rapid deterioration in their renal 
function, but Guay-Woodford and Desmond (2003) in their NAC could not attribute the 
delayed growth to specific causal factors in all cases. All 16 subjects with GR in the present 
study had evidence of CRI and HT. Thus the particularly high incidence of GR in this, 
compared to other studies, may reflect the relatively high incidence of CRI which in turn, may 
be partly a function of the long observation period of this study. 
4.5.5 Gender differences 
In keeping with the NAC data of Guay-Woodford and Desmond (2003), UTIs were found to 
be significantly more common in females, a fact that is well appreciated in general, and not 
specific to ARPKD. The increased incidence in females is thought to be due to anatomical 
differences between the normal male and female urinary tracts (Elder 2007). Also in keeping 
with the NAC data, there were no significant differences in the frequency of any other 
ARPKD related morbidities in this study when stratified by gender. This contrasts with Zerres 
et al (1996) (N=115) who found both a higher mortality rate in females and increased 
frequency of growth retardation and more severe renal disease in females. No explanation was 
given for these differences, and data in the present study  do not support these findings. 
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4.6 CORRELATION AMONG ARPKD COMORBIDITIES 
It is interesting, although not entirely explicable, that correlations were found overall in our 
cohort between the two renal morbidities (CRI and hypertension) and the hepatic morbidity 
(splenomegaly), but these were not significant in affected females. The discrepancy may be 
because this analysis was done with such small numbers of patients and would need validation 
in a larger group. Overall though, it is possible to conclude that the progression of disease in 
the homozygous subject group does not appear to be organ specific.  
 
Gagnadoux et al. (1989) found no relationship between renal and hepatic involvement in 
affected individuals and this was supported in the younger NAC (Guay-Woodford and 
Desmond 2003) by a lack of correlation between both renal morbidities and PHT. However, 
the large study (n=186) by Bergmann et al. (2005), as with the present study, did not support 
the findings in the NAC: renal morbidities were positively correlated with hepatic morbidities, 
and patients who appeared to exhibit an organ specific phenotype were regarded as exceptions. 
They suggest that genotype-phenotype correlations in patients with such organ specific 
presentations require further exploration, as does the role of genetic and environmental 
modifiers. 
4.7 MANAGEMENT 
4.7.1 Renal Replacement Therapy and Renal Survival 
Renal transplant was performed in 12/27 (44%) subjects in the present study at a median of 
14.6 years (mean of 13.7 years), older than the median of 4.4 years in the NAC born after 
1990. Communication between the writer and Professor P Thomson, previously head of 
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Paediatric Nephrology at Johannesburg Hospital, indicates that the criteria used for renal 
transplant (similar to those used internationally) and the availability of resources do not 
account for the large difference. While the long observation period may account for some of 
the difference it is possible that a milder renal phenotype in the p.M627K homozygotes may 
partly explain the later need for renal transplant.  
 
Mean renal survival (calculated from birth with an endpoint at the start of RRT, or death due 
to end stage renal disease), of 14.72 years in the present study is slightly longer than the 10.1 
years reported by Bergmann et al. (2005) in a subset of patients (N=11) carrying missense 
mutations on both alleles, and twice as long as their subset of patients (N=16) carrying a 
truncating mutation on one of the mutated alleles. This again may indicate that homozygotes 
carrying the missense p.M627K mutation have, as a group, a less severe renal phenotype than 
the mutationally heterogenous groups described above. Bergmann’s (2005) study also 
indicated that all patients carrying a truncating mutation on both alleles died shortly after birth, 
providing evidence of some degree of genotype-phenotype correlation. 
4.7.2 Interventions for hepatic related morbidities 
PHT resulting in hypersplenism that was clinically severe enough to require intervention 
occurred in 10 patients in the present study, including variceal banding in one, splenic shunts 
in five, embolisation of the splenic artery in three and splenectomy in three (two of whom had 
prior procedures). Details regarding interventions for hypersplenism were not available in 
other studies. It was thus not possible to compare the severity of the PHT in the present study 
with others, despite the apparent high incidence discussed in 4.5.3. 
 67 
 
Altogether 2.4% and 7% of the older (born before 1990) and younger patients, respectively, in 
the NAC (Guay-Woodford and Desmond 2003) received liver transplants. Liver transplant 
was not a therapeutic option available to the patients in the present study, and the number of 
patients who may have met criteria for liver transplant could not be assessed from the 
available data.  
4.8 SURVIVAL  
Three (11%) of the homozygous subjects died within the first month of life, with no further 
deaths in the remainder of the first year, translating to an 89% survival rate at one year. This is 
comparable to previous studies including that of Zerres (1996) who reported an identical 
survival rate at one year, Gagnadoux (1999), who reported a 91% survival rate at one year, 
and more recently, Guay-Woodford and Desmond (2003) who reported a 79% survival rate for 
the same period in their cohort of patients born after 1990. They suggested that recent 
therapeutic advances in neonatal and paediatric management have thus had little clinical 
impact on the outcome of patients with ARPKD and the present study supports this finding. 
The ascertainment of patients in the context of tertiary nephrology referral centers (in the 
majority studies included in Appendix B), must of course be considered in interpretation of the 
relatively good early survival rates. The under representation of patients dying in the perinatal 
or early neonatal period in all these studies cannot be accurately estimated. 
 
Only Kaariainen et al (1988), working in Finland, demonstrated a lower survival rate of 19% 
(14/73 subjects) (see Appendix B), but it appears that this was a diagnostically broad and 
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difficult to classify group (including all polycystic kidney disease patients) as the analysis was 
made mainly from the Finnish death registers. When attempts were made to sub-classify the 
patients, survival to one year of the ARPKD patients was 42%, more in keeping with the 
estimate of Zerres (1998a) and supporting evidence of the bias toward long term survivors 
when nephrology centers ascertain patient cohorts. 
 
Although a number of patients were lost to follow up during the first 20 years of observation, 
no further deaths were recorded in the present study until after 20 years of age and the mean 
survival was 21.45 years. This finding is difficult to compare to other published studies where 
the mean observation periods were shorter. In the older NAC patients (Guay-Woodford and 
Desmond 2003), born before 1990, no deaths after one year of age were reported. Survival 
beyond the first year of life, and more specifically the neonatal period, appears to be better 
than is generally perceived, as suggested by Guay-Woodford and Desmond (2003) and 
supported by the present study. 
4.9 SIBSHIPS 
There were 4 families in which more than one sibling was affected with ARPKD. 
Unfortunately, clinical data were not available for all of these patients (10), thus it was not 
possible to assess detailed differences within each sibship. However, in terms of survival, the 
discordance within the first three families was clear, with one sibling dying in the first six 
months and the other/s surviving into the second or third decades.  
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On initial observation, it may seem apparent that the first sibling tends to do worse, and that 
perhaps with increased awareness and earlier management, subsequent siblings are at a 
survival advantage. However the number of sibships (four) is too small to draw such a 
conclusion. In addition, in families 2 and 3, the first sibling is reported to have had severe 
pulmonary hypoplasia, which was not apparent in the next sibling. Sibling 1 in family 1 died 
of sepsis at 5 months, while his brothers had a relatively uncomplicated early course and were 
in fact only diagnosed with ARPKD at 0.5 and 1.3 years respectively.  
 
This discordance among sibships has been well documented. Kaplan et al. (1989a) reported 
eight families, six of whom were discordant for age and mode of onset. This was in contrast to 
Kaariainen (1987) who noted familial consistency for perinatal presentation in 11 families. Of 
the twenty sibships studied by Deget et al. (1995), only nine sibling pairs demonstrated the 
same clinical subtype (according to Blyth’s and Ockenden’s (1971) classification of perinatal, 
neonatal, infantile and juvenile forms).  Eight families of the 11 in which one sibling had died, 
showed markedly discordant ages of death with one death postnatally, and the second sibling 
surviving to the date of last examination (8 months to 14 years). The affected sibling with the 
early death was the first born in six of the eight families, but as with the present study the 
complications occurred early on in the first sibling, and the clinical course of the second was 
milder, indicating that the survival with increased birth order is unlikely to be due to 
opportunities for more aggressive treatment in the second child. More recently Bergmann et 
al. (2005) reported that overall the majority of sibships display comparable clinical courses 
with about 20% exhibiting gross intrafamilial variability in phenotype, in their unpublished 
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data of more than 100 pedigrees. In that study, however, gross variability with respect to 
survival was found in 20 out of 48 sibships (42%) studied. Of these 20, the firstborn faired 
worse in 14 (70%) of the sibships. They comment that these results may indicate a bias as a 
result of the study design requiring at least one neonatal survivor per family. The present study 
may also be biased toward this as primary ascertainment was usually of the longer surviving 




The pathogenic missense p.M627K mutation was detected in 81% of ARPKD disease 
associated alleles in the Afrikaner population. This significant finding supports the use of 
targeted mutation analysis in Afrikaans patients with a suspected clinical diagnosis of 
ARPKD, decreasing the need for renal biopsy and increasing the cost-effectiveness of 
diagnosis. Accurate prenatal diagnosis is feasible, without the need for a confirmed 
histological diagnosis in a sibling, and with increased accuracy compared to the previously 
used molecular method of linkage analysis. 
 
Marked clinical variability was demonstrated within the subject group of affected individuals 
homozygous for the p.M627K mutation in the present study, supporting the limited genotype-
phenotype correlation described worldwide, particularly among individuals with two missense 
mutations accounting for their disease. The findings in this study were compared to previously 
described cohorts representing diverse mutational spectrums and as with those studies, a wide 
degree of phenotypic variability was evident, despite the local genetic homogeneity. The 
limited genotype-phenotype correlation for this condition was further demonstrated by vast 
discordance in survival in three of the four affected sibships observed.  
  
ARPKD was diagnosed at a median age of 27 days, older than a North American cohort born 
after 1990 (median age of one day). While the vast majority of subjects in the present study 
were diagnosed with CRI and HT, indicating the renal morbidities to be more common than in 
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previously described cohorts, these morbidities occurred at a later median age than in most 
studies, possibly indicating a trend to a milder expression of renal morbidity in homozygotes 
for the p.M627K mutation. Further support for this conclusion lies in the later median age of 
renal transplant (14.6 years vs 4.4 years in the NAC). PHT was diagnosed in the present study 
more frequently than in previous studies, at a younger median age, although with similar 
complication rates. Statistical overall correlation was found between the renal and hepatic 
related morbidities in this study, indicating that progression of the ARPKD is not organ 
specific in this homozygous subject group, in contrast with findings in the NAC but in keeping 
with other previous studies such as Bergmann et al. 2005. The survival rate of 89% at one year 
in the present study was not dissimilar to previous studies with similar patient ascertainment.  
 
Correlation of an underlying molecular defect with the clinical course of a condition aims to 
improve both the care given to an affected family as well as provide a better understanding of 
the molecular pathogenesis of the condition. From the findings in this study, aside from a 
possibly milder course of the renal disease, and earlier onset of PHT, no genotype specific 
phenotype patterns are evident. The degree of intra-familial variability in terms survival 
further supports the limited correlation. Additional genetic and/or environmental factors must 
account for the variability seen in these patients with comparable genotypes. 
 
This group represents a unique cohort and is the largest series of patients affected by ARPKD 
homozygous for a single mutation, described to date. The findings from this study in 
conjunction with the presence and availability of testing for the p.M627K mutation in the 
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Afrikaans population will provide for more accurate, specific and informative genetic 
counselling in families affected by ARPKD, as well as accurate, rapid and cost effective 
prenatal diagnosis in situations where it is requested.  
 
Continued collaboration with the University of Alabama at Birmingham (USA) Recessive 
Polycystic Kidney Disease Core Center (UAB RPKDCC), under the directorship of Professor 
L Guay-Woodford will enable future studies to be undertaken. This subject group presents a 
valuable and unique resource for future studies of modifier genes and environmental 
influences on the phenotypic expression of ARPKD. The additional data from the group of ten 
individuals, compound heterozygotes for the p.M627K and another mutation, which was not 
analysed for the purposes of this study, may contribute to future genetic modifier studies.  
 
Further follow up of the patients who remain in contact with the various nephrology units will 
provide additional valuable information regarding the natural history of ARPKD within a 
genetically homogenous setting. Finally, further studies should also aim to supplement the 
current data with newly diagnosed patients countrywide as well as existing patients in the 
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Appendix B: Summary of findings of previous studies compared with the Afrikaans homozygous cohort 
 
  The present 
study(2006) 






Roy et al 
(1997) 








Patients,n 27 186(164) 166 31 52 115 33 55 18 17 
m:f 1.18   0.96     1.35 N/A 1.39 N/A N/A 
Age at 
diagnosis 
0% prenatal 23% prenatal 46% prenatal 32% prenatal  11% prenatal    Diagnosed in 
1st year 
  
50% <1 month 31% <1 month 27% < 1 month 23% < 1 
month 










85% <1 year 23% <= 1 year 55% 
<18months 
45% <=1year 6% <=1year  
  
12% >1year 30% >1year 16% >1year 26% >1year 15% >1year 25% >1year 12% 6-11 
years 
10% >1year 22% >1year  
Hyponatraemia 33% NA 26% 10% NA 6% 18%  33%(6/18) NA 
Growth 
Retardation 
59% 16% <2SD 24% NA NA 25% 18% 
(6/33)<4SD 
NA 6% (1/18) 
<2.5SD 
NA 




  29%ESRD by 
10y 
13%ESRD  16%ESRD  33%ESRD by 
15y 




93% 76% 65% 55% 60% (by 15 
years) 






44% 15% 37% 23% (8/35) 46% 39%(13/33) 47% 11% (2/18) 35%(6/17) 
  
  38% 
splenomegally 
         
Survival rate   85% 1y 79% 1y 87% 1y NA 89% 1y 91% 1y (30/33) 




89% 5y 84% 5y 75% 5y 80% 9y  88% 3y  51% 10 y   
  
89% 20yr 82% 10yr       46% 15y   
Death rate in 
1st year 
11% 8% (survivors of 
1st month) 






100% 5yr 86% 5y         
  
90% 10yr 71% 10yr         
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Appendix C: Consent forms and ethics clearance 
 
STUDY OF AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE IN 
AFRIKAANS FAMILIES 
 




My name is Dr Lindsay Lambie. I work in the Department of Paediatrics, Renal Unit, 
at Johannesburg Hospital and with the Division of Human Genetics at the National 
Health Laboratory Service and University of the Witwatersrand. 
 
We are doing a study to describe the clinical features of patients diagnosed with 
autosomal recessive polycystic kidney disease (ARPKD), and to find out if there is a 
common gene fault (mutation) that causes this problem in Afrikaans families. As you 
know, your child has been diagnosed with this condition. 
 
We know that ARPKD is a rare inherited disease, and that all affected individuals are 
not equally affected – some are more severely affected than others. To get the 
disease, a child needs to inherit this gene fault from both parents, and will have two 
faults. The parents are both well because they only have one fault each.  
 
Worldwide ARPKD affects 1 in 20 000 people, but in the Afrikaans population ARPKD 
occurs more commonly. This is thought to be because the disease was present 
among the small number of settlers who originally came to South Africa, and today’s 
Afrikaans population grew from that small group.  
 
The gene that causes ARPKD has recently been found, but so far, the specific fault in 
Afrikaans families has not been identified.  
 
Since some patients are more severely affected than others, and yet many may have 
the same specific genetic fault, there must be other factors as well, that determine the 
severity of each patient. We would therefore also like to see if a common specific fault 
can be connected to certain clinical features.  
 
You do not have to take part in this study, but if you agree, we would ask whether you 
would be prepared to allow us to look at your child’s hospital and / or genetic 
counselling files. This personal information will remain confidential, and will not be 
passed on to anyone without further written consent. The information will be coded 
(only I will know from whom it originated) and compared with other patients who have 
ARPKD. To make sure we have complete and accurate information, I may need to 
ask you a few questions, related to your child’s condition, after looking at the records. 
This would take about 30 minutes and would be done at your convenience.  
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In addition, if you agree to take part in the study, we would ask to obtain a sample of 
blood from your child, as well as both the parents. We will need about 10ml (2 
teaspoonsful) of blood from each individual. I, Dr Lindsay Lambie, will do the 
procedure. The procedure is safe, and there is only a slight prick as the needle is 
placed through the skin. If your child requires any routine blood sampling for ongoing 
management, we could collect the study sample at the same time, thus not requiring 
an extra prick. 
 
These blood samples will be numbered, and sent to the laboratory, where the genetic 
material (DNA) will be extracted. This DNA will be used to look for the genetic fault 
that causes ARPKD. We will also ask that once the study is complete, we may store 
the rest of the blood, again this will be coded to protect your privacy. If you specifically 
agree, we may use these samples for future research, related to ARPKD. 
 
Remember that this study is completely voluntary, and you may choose not to take 
part, or may withdraw at any time. This carries no penalty, and will not influence your 
child’s ongoing treatment, or any genetic counselling or assistance you may require in 
future. 
 
This study may not provide any direct benefit to yourself or your child, but may help 
us understand more about ARPKD, and benefit those with the condition in future, in 
terms of more accurate genetic counselling, and perhaps prenatal diagnosis. 
However, if we are able to identify the specific gene fault, we could, at your request, 
let you know these results. These results may not be informative and may not benefit 
you directly. The results would not change the treatment or diagnosis of your child. 
 
If you have any questions about the study, you can contact myself at telephone 
number 082 787 7134, or Professor Amanda Krause at 011 489 9224. 
 
This study has been approved by the Postgraduate and Ethics Committees of the 
University of the Witwatersrand. 
 
If you agree to participate, please could you read and sign the attached consent 
forms (each parent should sign a separate consent form). 
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I,__________________________, parent of _________________________, have 




1. Give permission for review of my child’s clinical records, and understand 
that the information will be kept confidential. 
2. Agree to a short interview, related to my child’s condition, in order for you 
to complete the records. 
3. Agree to collection of a sample of blood from me, and from my child, to be 
used for this study. 
 
I do / do not (delete whichever is not applicable) wish to be informed of any results. If 
so, a counseling session will be arranged, in about 9 months time. 
 
I do / do not (delete whichever is not applicable) give permission for the blood 
samples to be stored, and used in further studies related only and directly to ARPKD. 
 
I understand that participation in this study is voluntary, and we may withdraw at any 
time. A decision not to participate will not influence future management in any way. I 
also understand that participation in this study will provide no direct benefit to myself 
or my child, and will not change the ongoing management or diagnosis. 
 
Signed: ______________________________ (Parent) 
 
Contact Telephone number: __________________ 
 
Date:     __________________ 
 
 
Witness:  __________________ 
 
Date:  __________________ 
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My name is Dr Lindsay Lambie. I work in the Department of Paediatrics at 
Johannesburg Hospital, with children who have kidney problems. We are doing a 
study about the type of kidney disease that you have. We are trying to find out what 
exactly causes this problem, and why some children with this disease are more sick 
than others. 
 
To do this, we need to look at your hospital files, talk with your parents, and take a 
small sample of blood (about 10ml, which is the same as 2 teaspoonsful) from your 
arm. We can try to do this at the time we take your other blood tests, if you need 
them. If not, we will just take blood for this. As you know, when we take blood, it is a 
quick prick, which is uncomfortable as the needle goes through the skin, but does not 
cause any harm.  
 
All the information from your files is private (no one else will be allowed to see them).  
 
This study will not help you directly – it will not help to make you better. Your 
treatment will continue just as before. This study will help doctors to understand your 
problem better, and may help other families in the future. 
 
Please let us know if you agree to taking part in this study.   
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